Matches in Wikidata for { <http://www.wikidata.org/entity/Q95656602> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- Q95656602 description "artículu científicu espublizáu en mayu de 2020" @default.
- Q95656602 description "scientific article published on 24 May 2020" @default.
- Q95656602 description "wetenschappelijk artikel" @default.
- Q95656602 description "наукова стаття, опублікована 24 травня 2020" @default.
- Q95656602 name "Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study" @default.
- Q95656602 name "Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study" @default.
- Q95656602 type Item @default.
- Q95656602 label "Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study" @default.
- Q95656602 label "Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study" @default.
- Q95656602 prefLabel "Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study" @default.
- Q95656602 prefLabel "Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study" @default.
- Q95656602 P1433 Q95656602-042DE40E-C7C0-4C01-AA1D-1E2C141720F4 @default.
- Q95656602 P1476 Q95656602-2D4326DE-2260-4A61-B2BF-C122A8064F1B @default.
- Q95656602 P2093 Q95656602-09DFB0D6-D11E-4641-94E9-662F836AB805 @default.
- Q95656602 P2093 Q95656602-0A222104-AF76-4935-8E16-53EBB421FD09 @default.
- Q95656602 P2093 Q95656602-0B0B2D5F-8DFA-41E8-A3C1-8CB5693317AF @default.
- Q95656602 P2093 Q95656602-15C24FEA-607B-4A9E-829B-317117A4CBC0 @default.
- Q95656602 P2093 Q95656602-243B449F-006F-4421-B39E-B608E89EE15A @default.
- Q95656602 P2093 Q95656602-2E9F236C-1B01-4EBB-AFF8-AB7F17DF6C06 @default.
- Q95656602 P2093 Q95656602-39AADD83-E78D-4967-B352-640CE3D92BB8 @default.
- Q95656602 P2093 Q95656602-455992FC-F84D-431F-A055-E8B400F40D27 @default.
- Q95656602 P2093 Q95656602-8062B326-6E87-4C6F-A713-0105AB75FD71 @default.
- Q95656602 P2093 Q95656602-82D5A652-90A3-4FE0-979D-A5CAFD0AEB81 @default.
- Q95656602 P2093 Q95656602-95EEF411-8E4F-4DBA-948C-77C48C685592 @default.
- Q95656602 P2093 Q95656602-AF4A2142-47D0-4D7C-9404-813FE602F6C3 @default.
- Q95656602 P2093 Q95656602-B1BE8525-1A97-4388-9CA9-E02F9DDD2C22 @default.
- Q95656602 P2093 Q95656602-C508A749-F13F-448B-8F83-9E75B20342DE @default.
- Q95656602 P2093 Q95656602-D29544DD-BCEB-411F-8C0D-F9AF1E601121 @default.
- Q95656602 P2093 Q95656602-D64B3F5C-14FD-40D0-9BC5-281E9EA9151E @default.
- Q95656602 P2093 Q95656602-DD48FDF6-D8C7-4DD5-94FF-0A1B3EF54AAE @default.
- Q95656602 P2093 Q95656602-E44E4085-2C6B-4A40-B15D-174910563FD1 @default.
- Q95656602 P31 Q95656602-E129E1B2-A0B0-4CDD-8AFF-01382F6BC3F7 @default.
- Q95656602 P356 Q95656602-85EB3B8F-60D3-4B30-8F9A-22096A787220 @default.
- Q95656602 P50 Q95656602-06DBEE30-A4EB-4358-8FEB-87969FFC5D83 @default.
- Q95656602 P50 Q95656602-09F55D19-0F9E-4A65-8E5C-A5F3A9A4EBF3 @default.
- Q95656602 P50 Q95656602-C73BCA12-F822-4518-A060-2A1A7E680D91 @default.
- Q95656602 P50 Q95656602-DA05E49C-5784-4CA0-84C3-88F86D993D53 @default.
- Q95656602 P577 Q95656602-CFD479AB-05EB-4CBD-AE80-868A84B20F9C @default.
- Q95656602 P698 Q95656602-C13ADC0D-5503-40AD-AE51-D3BA14BF07EB @default.
- Q95656602 P356 BJH.16733 @default.
- Q95656602 P698 32449159 @default.
- Q95656602 P1433 Q4970200 @default.
- Q95656602 P1476 "Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study" @default.
- Q95656602 P2093 "Brian Huntly" @default.
- Q95656602 P2093 "Dragana Milojkovic" @default.
- Q95656602 P2093 "Fenella Willis" @default.
- Q95656602 P2093 "Fiona Glen" @default.
- Q95656602 P2093 "Fiona L Dignan" @default.
- Q95656602 P2093 "Gavin Campbell" @default.
- Q95656602 P2093 "Jacqueline Ryan" @default.
- Q95656602 P2093 "Jane Tighe" @default.
- Q95656602 P2093 "Jenny Byrne" @default.
- Q95656602 P2093 "Louise Fildes" @default.
- Q95656602 P2093 "Manoj Raghavan" @default.
- Q95656602 P2093 "Mark Drummond" @default.
- Q95656602 P2093 "Muttuswamy Sivakumaran" @default.
- Q95656602 P2093 "Pratap Neelakantan" @default.
- Q95656602 P2093 "Richard E Clark" @default.
- Q95656602 P2093 "Sahra Ali" @default.
- Q95656602 P2093 "Sarah J Collington" @default.
- Q95656602 P2093 "Scott Marshall" @default.
- Q95656602 P31 Q13442814 @default.
- Q95656602 P356 "10.1111/BJH.16733" @default.
- Q95656602 P50 Q42628914 @default.
- Q95656602 P50 Q57032592 @default.
- Q95656602 P50 Q89312191 @default.
- Q95656602 P50 Q95656597 @default.
- Q95656602 P577 "2020-05-24T00:00:00Z" @default.
- Q95656602 P698 "32449159" @default.